Assessing Individual and Disseminated Effects in Network-Randomized Studies by Buchanan, Ashley L et al.
University of Rhode Island
DigitalCommons@URI
Pharmacy Practice Faculty Publications Pharmacy Practice
2018
Assessing Individual and Disseminated Effects in
Network-Randomized Studies
Ashley L. Buchanan
University of Rhode Island, buchanan@uri.edu
Sten H. Vermund
See next page for additional authors
Follow this and additional works at: https://digitalcommons.uri.edu/php_facpubs
The University of Rhode Island Faculty have made this article openly available.
Please let us know how Open Access to this research benefits you.
This is a pre-publication author manuscript of the final, published article.
Terms of Use
This article is made available under the terms and conditions applicable towards Open Access Policy
Articles, as set forth in our Terms of Use.
This Article is brought to you for free and open access by the Pharmacy Practice at DigitalCommons@URI. It has been accepted for inclusion in
Pharmacy Practice Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Ashley L Buchanan, Sten H Vermund, Samuel R Friedman, Donna Spiegelman; Assessing Individual and Disseminated Effects in
Network-Randomized Studies, American Journal of Epidemiology, , kwy149, https://doi.org/10.1093/aje/kwy149
Available at: https://doi.org/10.1093/aje/kwy149
Authors
Ashley L. Buchanan, Sten H. Vermund, Samuel R. Friedman, and Donna Spiegelman
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/php_facpubs/104
Assessing Individual and Disseminated Effects in Network-Randomized 
Studies 
 
Ashley L. Buchanan, Sten H. Vermund, Samuel R. Friedman, and Donna Spiegelman 
 
Correspondence to Dr. Ashley Buchanan, Department of Pharmacy Practice, College 
of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, RI 02881 
(email: Buchanan@uri.edu; phone: 401-874-4739; fax: 401-874-2717) 
 
Author affiliations: Department of Pharmacy Practice, College of Pharmacy, 
University of Rhode Island, Kingston, Rhode Island (Ashley L. Buchanan); Vanderbilt 
Institute for Global Health and Department of Pediatrics2, Vanderbilt University 
School of Medicine, New Haven, Connecticut (Sten H. Vermund); Institute for 
Infectious Disease Research, National Development and Research Institutes, Inc., 
New York, New York (Samuel R. Friedman); Departments of Epidemiology, 
Biostatistics, Nutrition, and Global Health and Population, Harvard T.H. Chan School 
of Public Health, Boston, MA (Donna Spiegelman) 
 
Funding: ALB and DS were supported by the National Institutes of Health (NIH) 
grants 5R01AI112339-02 and 1DP1ES025459 (DP1). SHV was supported by NIH 
grants UM1AI068619, 5R01AI112339, and P30AI110527. SRF was supported by 
NIH grants DP1DA034989 and P30DA011041. The content is solely the 
responsibility of the authors and does not necessarily represent the official views of 
the National Institutes of Health. 
 
Conflicts of interest: None declared. 
 
Running Head: Network-Randomized Studies with Dissemination 
 
   
 
 
Network-Randomized Studies with Dissemination 
2 
Abbreviations: Confidence interval (CI), Generalized estimating equations (GEEs), 
HIV Prevention Trials Network (HPTN), Human Immunodeficiency Virus (HIV), 
Risk/Rate difference (RD), Risk/Rate ratio (RR) 
 
  
   
 
 
Network-Randomized Studies with Dissemination 
3 
ABSTRACT 
Implementation trials often involve clustering via risk networks, where only some 
participants directly received the intervention. The individual effect is that among 
directly treated persons beyond being in an intervention network; the disseminated 
effect is that among persons engaged with those directly treated. We employ a 
causal inference framework and discuss assumptions and estimators for individual 
and disseminated effects and apply them to HIV Prevention Trials Network 037. HIV 
Prevention Trials Network 037 was a Phase III, network-level, randomized 
controlled HIV prevention trial conducted in the US and Thailand from 2002 to 2006 
that recruited persons who injected drugs, who received either intervention or 
control, and their risk network members, who received no direct intervention. 
Combining individual and disseminated, a 35% composite rate reduction was 
observed in the adjusted model (95% confidence interval = 0.47, 0.90). Methodology 
is now available to estimate the full set of these effects enhancing knowledge gained 
from network-randomized trials. Although the overall effect gains validity from 
network randomization, we show that it will, in general, be less than the composite 
effect. Additionally, if only index participants benefit from the intervention, as the 
network size increases, the overall effect tends to the null, an unfortunate and 
misleading conclusion.  
Keywords: Causal inference; Cluster-randomized trials; Disseminated/Indirect 
effects; Drug use/abuse; HIV/AIDS; Implementation Science; Individual/Direct 
effects; Interference  
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Implementation science studies how best to translate and scale-up research 
evidence into practice. These studies often involve a natural clustering by social 
network, facility or community. In such network-randomized trials, only some 
members of networks randomized to the intervention directly receive the 
intervention. Individual and disseminated effects can be targets of inference. The 
disseminated or indirect effect is the impact of the intervention on the network 
members who were not directly exposed in the intervention networks. The 
individual or direct effect is the impact of the intervention on those who directly 
received the intervention, the index participants in intervention networks, beyond 
being an intervention network member. The composite effect is the effect of the 
intervention on index participants compared to network control members; that is, 
the maximal attainable benefit of the intervention. For example, a health care 
professional may educate an index participant, also known as the ego, who then in 
turn may educate or otherwise influence members of his or her risk network, also 
known as the alter-egos, to modify their risky practices. In this setting, there is 
interest in the intervention effect on those who were directly educated as well as 
those sharing risk networks with the index.  
The terms individual and disseminated are used in this paper to avoid 
confusion with these terms used in the mediation literature, where the direct and 
indirect effects are terms used to describe parameters addressing different scientific 
questions (1). We present a summary of the vernacular from relevant literature on 
the present topic and provide our recommended terms in Table 1. Compared to 
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previous terminology, our terms are more agnostic to the relative magnitudes and 
desirability of dissemination.  
 In causal inference methodology, a fundamental assumption of much work is 
the stable unit treatment value assumption, that is, SUTVA (2), which includes an 
assumption of no dissemination, or interference, between individuals. No 
dissemination requires that the potential outcomes of one individual are unaffected 
by the intervention assignment of other individuals. In this paper, the primary 
research interest is precisely in relaxing the no dissemination assumption of the 
stable unit treatment value assumption and quantifying disseminated effects.  
 Earlier work on methods for assessing dissemination assumed two-stage 
randomization, where networks were first randomized to an intervention allocation 
strategy and, then, within a network, individuals were randomized according to 
their network’s allocation strategy (3, 4). Estimators of individual and disseminated 
effects were motivated by vaccine studies, where herd immunity is a good example 
of a disseminated effect (5, 6). Permutation-based variance estimators were 
developed for these doubly-randomized designs (4).  When a study is not doubly 
randomized, these estimators of individual and disseminated effects are no longer 
valid because of the potential for bias due to confounding at either the network-, 
individual- level or both. Tchetgen Tchetgen and VanderWeele (7) proposed inverse 
probability weighted estimators of individual and disseminated effects for studies 
where randomization is not required at the individual or group level. This approach 
was applied to an individually-randomized study of cholera vaccine, where 
individuals were clustered by groups of households. (8). This approach was then 
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applied to a study design with more than one index member and unequal treatment 
probabilities in the second stage (9).  
Using multivariable outcome models rather than inverse probability 
weighted models, we develop alternative estimators of individual, disseminated and 
composite causal effects for a setting with randomization only at the network level 
and one index per network, a study design frequently utilized in drug abuse and 
addiction research (10-12), and provide methods for asymptotic inference. We 
discuss the causal inference framework and assumptions for this setting. We prove 
some general results of interest in this setting that demonstrate the utility of the 
methods proposed. We apply these methods to a network-randomized trial in the 
HIV Prevention Trials Network (HPTN)(13-15) to obtain estimates of the individual, 
disseminated, composite, and overall intervention effects. Lastly, we discuss some 
limitations of this approach and identify future methodological directions for causal 
inference in network-randomized studies. 
METHODS 
Assumptions and Notation 
The sufficient conditions for valid estimation of causal effects have been 
previously described (16) . We assume no dissemination between networks. 
Because the networks are randomized to the intervention, on average, 
exchangeability at the network level holds. Networks randomized to the 
intervention will be, on average, comparable to networks randomized to the control. 
There is an additional exchangeability assumption that allows for valid estimation of 
all the parameters of interest in this setting. Within each network, conditional on a 
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set of measured covariates, the potential outcomes of the voluntary index 
participants and non-index network members are the same as, on average, that 
would be expected if any other network member volunteered to be the index, 
whether the network was randomized to the intervention or not.  We call this 
“conditional index exchangeability”.  
Let 𝐾 be the total number of networks, 𝑘 = 1, … , 𝐾, with 𝑖 = 1, … , 𝑛𝑘 
participants in network 𝑘, where each participant 𝑖 has 𝑗 = 1, … , 𝑚𝑘𝑖 visits and 
∑ 𝑛𝑘 = 𝑁
𝐾
𝑘=1  is the total sample size of the study. Let 𝒁𝑘𝑖 be a vector of measured 
baseline covariates for participant 𝑖 in network 𝑘. Define 𝑌𝑘𝑖𝑗 as the outcome for the 
𝑖th participant in the 𝑘th network at the 𝑗th visit. Let 𝑋𝑘 be the network-level 
intervention in network 𝑘 assigned at the start of the trial and define an indicator 
𝑅𝑘𝑖 for the individual-level index status, where 𝑅𝑘𝑖 = 1 if participant 𝑖 in network 𝑘 
is an index and 𝑅𝑘𝑖 = 0 otherwise. For example, investigators assign HIV risk 
networks either to train their index member to be peer educator or standard of care 
with HIV counseling and testing. In network 𝑘, we have an 𝑛𝑘-vector of observed 
index status indicators 𝑹𝑘 = (𝑅𝑘1, 𝑅𝑘2, … , 𝑅𝑘𝑛𝑘), constrained in this paper 
to ∑ 𝑅𝑘𝑖
𝑛𝑘
𝑖=1 = 1 and 𝑛𝑘-vectors of baseline covariates 𝒁𝑘 = (𝑍𝑘1, 𝑍𝑘2, … , 𝑍𝑘𝑛𝑘). Each 
participant has potential outcomes 𝒀𝑘𝑖𝑗(𝒓, 𝑥), which correspond to the 2 × 𝑛𝑘 vector 
of potential outcomes for individual 𝑖 in network 𝑘 at time 𝑗 under the index status 
indicator vector 𝑹𝑘 = 𝒓 and intervention assignment 𝑋𝑘 = 𝑥. Because an 
individual’s potential outcomes depend on the network-level intervention, 
dissemination is possible in this setting. A contrast between any two of these 
potential outcomes is a measure of a causal effect. For example, a representation of 
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the individual causal effect in an intervention network where the second participant 
was the index compared to when the last participant was the index is 
𝐸{𝒀𝑘𝑖𝑗[(0,1, … 0), 1]} − 𝐸{𝒀𝑘𝑖𝑗[(0,1, … 1), 1]}. 
Because the number of index members in network 𝑘 is fixed to 1 by design, 
there are 𝐽𝑘 = (
𝑛𝑘
1
) = 𝑛𝑘 possible configurations of index participants in each 
network 𝑘. In general, each network member has 2 × 𝑛𝑘 potential outcomes with 𝑛𝑘 
corresponding to intervention and 𝑛𝑘 corresponding to control. With these many 
potential outcomes within networks, it is difficult to choose the causal effects of 
interest. Conditional on baseline covariates, we assume that there is exchangeability 
between the 2 × 𝑛𝑘 possible configurations when there is one index participant in 
network 𝑘; that is, 𝑌𝑘𝑖𝑗(𝒓, 𝑥) ⊥ 𝑹𝑘| 𝒁𝑘. Baseline covariates are sufficient to control 
for confounding of the effect of self-selected index status on the outcome. Because 
there is only one index per network, we can validly denote the potential outcomes 
by 𝑅𝑘𝑖 = 𝑟 and 𝑋𝑘 = 𝑥. Under these circumstances, the number of potential 
outcomes for each participant, 𝑌𝑘𝑖𝑗(𝑟, 𝑥), is reduced to four; that is, two for each of 
the two possible network-level intervention assignments, 𝑌𝑘𝑖𝑗(1,1), 
𝑌𝑘𝑖𝑗(1,0), 𝑌𝑘𝑖𝑗(0,1), and 𝑌𝑘𝑖𝑗(0,0).  For example, let 𝑌𝑘𝑖𝑗(1,1) be the potential outcome 
of participant 𝑖 at visit 𝑗 in network 𝑘, if, possibly contrary to fact, this participant 
was an index member in a network randomized to the intervention.  
Causal Framework and Estimands 
The individual effect is defined as the effect of the intervention among index 
members in intervention networks beyond being in an intervention network (Figure 
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1), that is, Risk/Rate DifferenceI (𝑅𝐷𝐼) = 𝐸[𝑌𝑘𝑖𝑗(1,1)] − 𝐸[𝑌𝑘𝑖𝑗(0,1)]. The 
disseminated effect is defined as the intervention effect among the non-index 
network members, that is, 𝑅𝐷𝐷 = 𝐸[𝑌𝑘𝑖𝑗(0,1)] −  𝐸[𝑌𝑘𝑖𝑗(0,0)].  Composite and 
overall effects combine the individual and disseminated effects in two different 
ways. The composite effect is the sum of the disseminated and individual effects, 
that is 𝑅𝐷𝐶𝑜𝑚𝑝 = 𝐸[𝑌𝑘𝑖𝑗(1,1)] − 𝐸[𝑌𝑘𝑖𝑗(0,1)] + {𝐸[𝑌𝑘𝑖𝑗(0,1)] −  𝐸[𝑌𝑘𝑖𝑗(0,0)]} =
𝐸[𝑌𝑘𝑖𝑗(1,1)] − 𝐸[𝑌𝑘𝑖𝑗(0,0)]. The composite effect is the maximum possible effect of 
the intervention; that is, the effect of being an index member in an intervention 
network compared to a network member in a control network.  
The overall effect is the average effect among all intervention network 
members compared to all control network members. In Web Appendix 1, we derive 
the parametric relationship between the individual and disseminated effects and the 
overall effect, and show that when network sizes vary, 𝑅𝐷𝑂𝑣𝑒𝑟𝑎𝑙𝑙 = 𝐸[𝑌𝑘𝑖𝑗(∙, 1)] −
𝐸[𝑌𝑘𝑖𝑗(∙, 0)] = 𝑅𝐷
𝐷 + 𝑅𝐷𝐼  ×  𝐸𝑅[𝑅𝑘𝑖] = 𝑅𝐷
𝐷 + 𝑅𝐷𝐼 ×
𝐾
𝑁
 , which will always be 
smaller than 𝑅𝐷𝐶𝑜𝑚𝑝 = 𝑅𝐷𝐷 + 𝑅𝐷𝐼 as long as 𝑅𝐷𝐼  and 𝑅𝐷𝐷  have the same sign, as 
would typically be the case. When network sizes are constant with 𝑛𝑘 = 𝑛 for all 𝑘, 
𝑅𝐷𝑂𝑣𝑒𝑟𝑎𝑙𝑙 = 𝑅𝐷𝐷 + 𝑅𝐷𝐼 ×
1
𝑛
. When the sign differs, the overall effect will be smaller 
than the composite only in certain cases. For example, if the average network size is 
3, 𝑅𝐷𝐼 = 1, and 𝑅𝐷𝐷 = −3, then 𝑅𝐷𝐶𝑜𝑚𝑝 = −2, which is smaller than 𝑅𝐷𝑂𝑣𝑒𝑟𝑎𝑙𝑙 =
−2.67. It is typically not expected for individual and disseminated effects to be in 
opposite directions, but it is technically possible. Because the overall effect depends 
on spurious features of the study design, including the size of the networks and the 
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number of index members, it will not be generalizable from one study to the next or 
to any scaled-up population, unless these features remain constant.   
When there is no disseminated effect, the overall will always be less than or 
equal to the composite. We also show that the overall effect will equal the composite 
only when the individual effect is null, a rather unlikely occurrence in our 
motivational setting. In Web Appendix 1, we also show properties for the 
relationship between the overall and composite risk ratio. 
Web Appendix 2 illustrates these relationships through some numerical 
studies motivated by HPTN 037.  If the individual and disseminated effects are in the 
same direction, the magnitude of the overall effect decreases as the network size 
increases. In the extreme, when there is no disseminated effect, the overall effect 
will approach the null as the network size increases, while the composite effect 
remains constant. 
Estimation and Inference for Individual and Disseminated Effects 
In network-randomized trials, the overall effect estimate has an immediate 
causal interpretation. In contrast, index status is not randomized. The indexes are 
recruited and then the remaining network members are recruited by the index. 
Hence, the individual, disseminated, and composite effects only have a causal 
interpretation when the estimator is fully adjusted for confounding.  
Generalized estimating equations (GEEs) (17) with a log link and working 
binomial variance can be used to estimate relative risks or rates, and an identity link 
and working binomial variance can be used to estimate risk or rate differences, and 
their confidence intervals adjusted for confounding (18, 19). These models also 
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adjust the estimated parameter variances for correlation within networks and, if the 
data are longitudinal, across visits within a participant. For log and identity links as 
employed in this paper, the conditional and marginal model parameters of interest 
are equivalent because the conditional mean is additive for the fixed and random 
effects; thus, the estimated effects can be interpreted as either participant-level 
and/or population-level estimates (20). 
One way to estimate these parameters is using an aggregate model. 
Assuming that the effects of the covariates 𝒁𝑘𝑖 are not modified by index status 𝑅𝑘𝑖 
and the linear model with the identity link fits the data, let 
 𝐸[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 , 𝑋𝑘 , 𝒁𝑘𝑖] =  𝛾0 + 𝛾1𝑅𝑘𝑖 + 𝛾2𝑋𝑘 + 𝛾3𝑋𝑘  𝑅𝑘𝑖 + 𝛾4𝒁𝑘𝑖 .  
It follows that the effect of being an index member in a control network is 
𝐸[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 = 1, 𝑋𝑘 = 0, 𝒁𝑘𝑖] − 𝐸[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 = 0, 𝑋𝑘 = 0, 𝒁𝑘𝑖] = 𝛾1. In a network 
randomized trial, there could be residual confounding even after adjusting for 
covariates 𝒁𝑘𝑖 , so subtracting off these terms accounts for possible unmeasured 
confounding due to self-selection of index status when estimating individual and 
composite effects (21, 22). Thus, the individual rate difference (RD) can be 
estimated by  
𝑅?̂?𝑎
𝐼 = ?̂?[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 = 1, 𝑋𝑘 = 1, 𝒁𝑘𝑖] − ?̂?[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 = 0, 𝑋𝑘 = 1, 𝒁𝑘𝑖] 
         −{?̂?[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 = 1, 𝑋𝑘 = 0, 𝒁𝑘𝑖] − ?̂?[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 = 0, 𝑋𝑘 = 0, 𝒁𝑘𝑖]} 
                            = 𝛾0 + 𝛾1 + 𝛾2 + 𝛾3 + 𝛾4𝒁𝑘𝑖 − (𝛾0 + 𝛾2 + 𝛾4𝒁𝑘𝑖) − 𝛾1 = 𝛾3. 
When estimating the disseminated effect, only information from non-index network 
members is included, therefore residual confounding of 𝑅𝑘𝑖 is not a concern. 
Adjustment for observed baseline covariates 𝒁𝑘𝑖 is needed because randomization 
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in the full study sample does not necessarily guarantee exchangeability of 𝑋𝑘 within 
subgroups of participants. The disseminated RD can be estimated by  
𝑅?̂?𝑎
𝐷 = ?̂?[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 = 0, 𝑋𝑘 = 1, 𝒁𝑘𝑖] − ?̂?[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 = 0, 𝑋𝑘 = 0, 𝒁𝑘𝑖] 
                            = 𝛾0 + 𝛾2 + 𝛾4𝒁𝑘𝑖 − (𝛾0 + 𝛾4𝒁𝑘𝑖) = 𝛾2. 
Similarly, the composite RD can be estimated by  
        𝑅?̂?𝑎
𝐶𝑜𝑚𝑝 = ?̂?[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 = 1, 𝑋𝑘 = 1, 𝒁𝑘𝑖] − ?̂?[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 = 0, 𝑋𝑘 = 0, 𝒁𝑘𝑖] 
    −{?̂?[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 = 1, 𝑋𝑘 = 0, 𝒁𝑘𝑖] − ?̂?[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 = 0, 𝑋𝑘 = 0, 𝒁𝑘𝑖]} 
                        =  𝛾0 + 𝛾1 + 𝛾2 + 𝛾3 + 𝛾4𝒁𝑘𝑖 − (𝛾0 + 𝛾4𝒁𝑘𝑖) − 𝛾1 = 𝛾2 + 𝛾3. 
Alternatively, if the effects of covariates 𝒁𝑘𝑖 differ by index status 𝑅𝑘𝑖, a stratified 
model could be used (Web Appendix 3). The estimators of the risk or rate ratio of 
the three effects of interest are defined analogously and can be estimated using a 
GEE with a log link and a working binomial variance.  SAS code provided in Web 
Appendix 4 demonstrates how to obtain these estimates and their corresponding 
variances. Analyses were performed using SAS Version 9.4 (Cary, NC). 
Illustrative Example 
The HPTN 037 study (23) was a Phase III randomized controlled HIV preventive 
intervention trial among people who inject drugs in the United States and Thailand 
(13). Following a network-randomized design, the index participants were eligible if 
they reported injecting drugs at least 12 times in the last three months, while the 
network members had to have injected drugs or had sex with the index member 
within the last three months. This study assessed the efficacy of a network-oriented 
peer education intervention to promote HIV risk reduction behaviors among people 
who inject drugs. Participants were followed for up to 30 months with visits 
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biannually with a median follow-up time of 18 months (Quartile 1 = 6, Quartile 3 = 
24) to obtain information on HIV incidence and risk behaviors. The study was 
underpowered for the primary outcome HIV incidence, so this analysis focused on 
the occurrence of reported HIV risk behaviors. Two sites participated, Chiang Mai, 
Thailand and Philadelphia, Pennsylvania, USA. At the time of this study, there was a 
“war on drugs” in Thailand, which may have reduced trust among people who inject 
drugs, possibly making the intervention less effective. Therefore, following the 
recommendation of the study investigators (Carl Latkin, Johns Hopkins Bloomberg 
School of Public Health, personal communication, 2016), this analysis only included 
participants at the Philadelphia site. Index participants whose network was 
randomized to the intervention arm received an educational intervention at 
baseline and education boosters at six and 12 months. Participants in both the 
intervention and control arms received HIV counseling and testing at each study 
visit. The primary analysis for this trial reported the overall effect estimated by a 
two-level GEE that accounted for correlations between participants within a 
network and between visits within participants (13). 
Shared cotton, an indicator for sharing needle/syringe “works”, was selected 
as an outcome because it nicely exemplified our methods. A more comprehensive 
clinical outcome, any injection-related risk behavior, included the following: sharing 
injection equipment (needles, cookers, cotton, and rinse water), front and back 
loading (i.e., injecting drugs from one syringe to another), injected with people not 
well known or in shooting gallery, and not properly disinfecting injection 
equipment. Following the original analysis of this study, these outcomes were 
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assessed among participants who reported injection drug use in the last six months 
at baseline. Statistical tests comparing prevalence of risk behaviors at baseline 
between network and index members were performed using a GEE model that 
accounted for within-network correlation.  
First, the cumulative incidence of ever reporting the outcome by 30 months 
of follow-up was analyzed using GEEs to account for correlations within networks, 
using the robust sandwich estimator with a working exchangeable correlation 
matrix (24, 25). Next, the longitudinal data were used to assess the effects of the 
intervention on the inter-visit incidence rates of sharing “works” and of any 
injection-related risk behavior using a multilevel GEE model. For estimation of the 
individual and disseminated effects, these models were adjusted for baseline 
covariates that were known or suspected risk factors for the outcome.  For a few 
outcomes, the models did not converge and log-Poisson models, which provide 
consistent but not fully efficient estimates of the relative risk, were used (26, 27). All 
statistical tests performed were two sided. 
RESULTS 
At the Philadelphia site of the HPTN 037 trial, there were 696 participants 
and 560 participants had at least one follow-up visit with a total of 1,598 person 
visits. At this site, 336 (48%) participants were in intervention networks (Table 2). 
At baseline, participants in intervention networks had a comparable prevalence of 
reported injection drug risk behavior (84%) compared to those in control networks 
(86%); however, index participants reported more risk behaviors at baseline (89%) 
as compared to network members (84%, P = 0.07). 
   
 
 
Network-Randomized Studies with Dissemination 
15 
Table 3 presents the cumulative incidence of the risk behavior sharing 
“works” and any report of injection-related risk behavior. Table 4 presents the 
results for the effects of the intervention on each outcome. For both outcomes, there 
was no evidence that the stratified model fit better than the aggregate model on 
either scale based on an informal comparison of the log likelihoods. Tables 5 and 6 
display the results of six-month inter-visit incidence rate differences and ratios for 
sharing “works” and any report of injection-related risk behavior from the 
longitudinal data. Based on an informal comparison of the log likelihoods, the 
stratified model was a better fit than the aggregate model on the ratio scale for both 
outcomes and on the difference scale for the any report outcome only.   
There was a significant 40% overall reduction on the ratio scale (95% 
confidence interval (CI): 8%, 61%) for the risk of ever sharing “works” by 30 months 
(Table 4). In contrast, there was a substantially larger, significant 61% reduction on 
the ratio scale in the adjusted composite risk of ever sharing “works” due to the 
intervention (95% CI: 22%, 80%). The individual effect was nearly twice as large as 
the disseminated effect, Risk Ratio (RR) = 0.52 vs. RR = 0.76, respectively.  
In the longitudinal data, the overall intervention effect was significantly 
protective with a 44% rate reduction on the ratio scale (95% CI: 11%, 65%) for 
sharing “works” (Table 5). Based upon the adjusted stratified models, there was a 
significant protective effect observed among network members with a 41% rate 
reduction on the ratio scale (95% CI = 3%, 64%), and a somewhat greater 59% 
individual rate reduction (95% CI = -6%, 84%).  A significant 76% composite 
adjusted rate reduction on the ratio scale was observed (95% CI = 45%, 89%).  
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For the risk of ever any report of risk behavior by 30 months, there was a 
near null individual effect, while the disseminated effect showed some suggestion of 
protection (Table 4). In the adjusted aggregate models, there was a non-statistically 
significant 17% reduction on the ratio scale in the composite risk of any report due 
to the intervention (95% CI = -10%, 38%) and a comparable overall risk reduction. 
The longitudinal analysis of the any injection-related risk behavior outcome 
demonstrated a statistically significant protective overall effect with a 28% rate 
reduction on the ratio scale (95% CI: 10%, 43%) (Table 6). Based on the adjusted 
stratified models, the intervention provided a 29% rate reduction on the ratio scale 
among network members (95% CI = 7%, 46%), but the individual effect did not 
achieve statistical significance (RR = 0.92, 95% CI = 0.60, 1.40). A significant 35% 
adjusted composite rate reduction on the ratio scale for any behavior was observed 
(95% CI = 10%, 53%). As a sensitivity analysis, we used a compound symmetric 
correlation matrix within a network between subjects and a first order 
autoregressive correlation matrix within subject over time and the results were 
comparable to those reported in Tables 5 and 6. 
DISCUSSION 
We developed estimators for individual and disseminated effects in network-
randomized trials. Because networks were randomized to the intervention, the 
overall effect estimate has a causal interpretation. However, the overall effect is 
influenced by ancillary factors, such as the size of the networks, and will typically 
underestimate the composite effect (See Web Appendices 1 and 2). When there is no 
unmeasured confounding and the model is correctly specified, individual and 
   
 
 
Network-Randomized Studies with Dissemination 
17 
disseminated effect estimates also have causal interpretations and provide a more 
in-depth understanding of the intervention’s impact.   
 In the HPTN trial, the overall effect of the intervention was statistically 
significant with an estimated 28% risk reduction of any injection-related risk 
behavior; however, although there was evidence for a significant 29% disseminated 
risk reduction, the individual effect did not achieve statistical significance for that 
same outcome. The original investigators reported only the overall effects (13), 
which we found were slightly to moderately attenuated compared to the composite 
effects that reveal the full power of the intervention.  Somewhat surprisingly, the 
disseminated effect was stronger than the individual effect for the report of any 
injection-related risk behavior, suggesting that this intervention has substantial 
resonance within the network beyond the effect of directly receiving the 
intervention. Without consideration of dissemination, efforts to understand the full 
array of mechanisms by which the intervention achieved its goal would be likely 
overlooked.  
The assumption of no unmeasured covariates associated with the treatment 
and outcome (or with the index status and outcome) cannot be empirically verified. 
For example, in HPTN 037, an individual’s unmeasured communication skills may 
affect whether or not they come forward to be an index and this may lead to 
unmeasured differences between index and non-index members. Future work could 
involve extensions to address unmeasured confounding when evaluating 
disseminated effects. In addition, the methods for incidence rate measures assume 
that there is no bias due to dependent loss-to-follow-up, and in the longitudinal 
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analysis, the missing visit process is ignorable (i.e., missing a visit is independent of 
the outcome conditional on intervention status and observed baseline covariates). If 
this assumption is questionable, censoring weights could be employed in the 
analysis (28, 29). These methods assume no dissemination between networks, 
although, it is possible in some settings that some network members will be in the 
risk networks of more than one index member. In HPTN 037, indexes may interact 
with participants outside their observed risk network because they may frequent 
the same neighborhoods and venues. These methods could thus be extended to 
accommodate dissemination between as well as within networks. In the HPTN trial, 
effect modification was observed for sex and participation in a drug treatment 
program. Future work could entail estimation of these within-strata effects and an 
application of such methods as g-estimation to ascertain population-level effects 
(30).  
These methods could also be extended to correct for bias due to 
misclassification or measurement error in the self-reported outcome or covariates 
(31). We assume that the reported effect estimates are not subject to social 
desirability effects, which could vary by intervention arm over time and 
dissemination may reinforce this.  Furthermore, the indexes may have 
underreported risk connections or study investigators may have missed some 
networks entirely. More accurate ways to elicit and recruit network member 
nominations and contact information could be developed and methods to infer 
unobserved or misclassified risk and social connections could be improved.  
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A network-based program implementation can be offered at a reduced cost, 
because only a subset of participants needs to receive the intervention. The example 
highlights the need for methods to adequately power trials to assess individual and 
disseminated effects. Future work could include evaluating the disseminated effects 
of treatment as prevention and similar interventions in HIV trials, including 
extensions for networks with more than one index participant (32-36). Extension of 
these methods to estimate both individual and disseminated effects of the 
components of multifaceted interventions is needed for future complex HIV/AIDS 
implementation science research, particularly that engaging drug-using or sexual 
risk networks. 
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Figure 1. Schematic diagram of the subsets of data used for each estimator 
(individual, disseminated, composite and overall) based on a format provided in (5) 
 
 
Control Network Intervention Network 
Network  
Members 
Network  
Members 
Index Index 
Individual Effect Disseminated Effect 
Overall Effect 
Composite Effect 
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Table 1. Related Terminology for Estimation of Individual and Disseminated Effects 
 
Recommended 
Term 
Alternative Terms Definition Parameter of Interest Network-Randomized  
Design Estimators 
Individual Direct Effect on those directly receiving 
intervention beyond being in an 
intervention network 
 
𝐸[𝑌𝑘𝑖𝑗(1,1)]
𝑐
− 𝐸[𝑌𝑘𝑖𝑗(0,1)]
𝑑
  
Aggregatea Stratifiedb 
 
𝛾3 
 
 
?̂?1 − ?̂?1 
Disseminated Indirect, Social Diffusion, 
Diffusion of Innovation, 
Contamination, Spillover 
Effect on those who received 
intervention indirectly through the 
index participant 
 
𝐸[𝑌𝑘𝑖𝑗(0,1)] − 𝐸[𝑌𝑘𝑖𝑗(0,0)]
𝑒 
 
𝛾2 
 
?̂?1 
Composite Total Combined individual and 
disseminated effects; Effect among 
indexes in intervention networks 
contrasted with effect among 
network members in control 
networks 
 
𝐸[𝑌𝑘𝑖𝑗(1,1)] − 𝐸[𝑌𝑘𝑖𝑗(0,0)]
  
𝛾2 + 𝛾3 
 
 
?̂?1 
Overallf Crude Effect among members of 
intervention networks contrasted 
with effect among members of 
control networks 
 
𝐸[𝑌𝑘𝑖𝑗(∙, 1)]
𝑔
− 𝐸[𝑌𝑘𝑖𝑗(∙, 0)]
ℎ
 
 
?̂?1
∗ 
 
 
a For a network-randomized design, rate difference parameters of the individual, disseminated, and composite effects, respectively, are estimated 
from an aggregate GEE model with an identity link and binomial variance: 
𝐸[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 , 𝑋𝑘 , 𝒁𝑘𝑖] =  𝛾0 + 𝛾1𝑅𝑘𝑖 + 𝛾2𝑋𝑘 + 𝛾3𝑋𝑘 𝑅𝑘𝑖 + 𝛾4𝒁𝑘𝑖 
b For a network-randomized design, rate difference parameters of the individual, disseminated, and composite effects, respectively, are estimated 
from a stratified GEE model with an identity link and binomial variance: 
𝐸[𝑌𝑘𝑖𝑗|𝑅𝑘𝑖 , 𝑋𝑘 , 𝒁𝑘𝑖] = 𝐼(𝑅𝑘𝑖 = 0) × (𝛽0 + 𝛽1𝑋𝑘 + 𝛽2𝒁𝑘𝑖)  + 𝐼(𝑅𝑘𝑖 = 1) × (𝛼0 + 𝛼1𝑋𝑘 + 𝛼2𝒁𝑘𝑖) 
c 𝑌𝑘𝑖𝑗(1,1) is the potential outcome of participant 𝑖 at visit 𝑗 in network 𝑘, if possibly contrary to fact, this participant was an index member in a 
network randomized to the intervention. 𝐸[𝑋] is the expectation of the random variable 𝑋.   
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d 𝑌𝑘𝑖𝑗(0,1) is the potential outcome of participant 𝑖 at visit 𝑗 in network 𝑘, if possibly contrary to fact, this participant was a network member in a 
network randomized to the intervention. 
e  𝑌𝑘𝑖𝑗(0,0) is the potential outcome of participant 𝑖 at visit 𝑗 in network 𝑘, if possibly contrary to fact, this participant was a network member in a 
network randomized to the control. 
f For network-randomized design, parameter of the overall effect is estimated from a GEE model with an identity link and binomial variance:  
𝐸[𝑌𝑘𝑖𝑗|𝑋𝑘] = 𝛽0
∗ + 𝛽1
∗𝑋𝑘  
g 𝑌𝑘𝑖𝑗(⋅ ,1) is the potential outcome of participant 𝑖 at visit 𝑗 in network 𝑘, if possibly contrary to fact, this participant was in a network randomized 
to the intervention. 
h 𝑌𝑘𝑖𝑗(⋅ ,0) is the potential outcome of participant 𝑖 at visit 𝑗 in network 𝑘, if possibly contrary to fact, this participant was in a network randomized 
to the control.   
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Table 2 Baseline characteristics of the HPTN 037 study population, Philadelphia 
site, 2002-2006, by treatment group (n = 696) 
 
 Network Randomizationa 
Characteristics  
Intervention  
% of (n = 336) 
Control 
% of (n = 360) 
Network Member Role   
       Index 33 33 
       Network member 67 67 
Network sizeb 3 (1.27) 3 (1.04) 
Male 68 69 
Age (years)b 41 (10) 40 (10) 
Drug treatment programb 22 32 
Housingc   
     Spent night on street, car, park or abandoned  
     building 
25 24 
     Spent time in jail 19 15 
Sexual riskd   
     More than one sex partner 42 40 
     Unprotected sex in the last week 50 50 
     Unprotected sex with non-primary  
      Partner 
16 19 
Injection drug behaviorse   
      Injection drug use in the last 6 month 93 94 
      Injection drug use in the last month 99 97 
           Heroin 94 96 
           Heroin w/ Cocaine 42 35 
           Heroin w/ Amphetamine 1 1 
           Cocaine 37 37 
           Amphetamine 2 2 
Number of days injected in the last month   
      0-5 9 9 
      6-14 8 9 
      15-29 24 16 
      Everyday 59 65 
Injection risk behaviors in the last monthf   
      Shared rinse water 44 51 
      Shared cooker 57 62 
      Shared cotton 41 46 
      Used front or back loaded syringe 21 23 
      Injected with an unclean syringe 13 15 
      Passed a syringe to someone else 48 53 
      Used a syringe after someone else 37 39 
      Injected with someone you don’t know  19 22 
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       well 
      Injected in a shooting gallery 61 56 
Did not clean syringe after use 14 13 
 
a There were 112 intervention networks and 120 control networks. Values of polytomous 
variables may not sum to 100% due to rounding.  
b Values are expressed as mean (standard deviation). 
c In past 6 months. 
d In last month. 
e Injection drug behaviors reported only for participants reporting injection drug use in the 
past 6 months. 
f Injection risk behaviors reported only for participants reporting injection drug use in the 
last month. 
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Table 3. Risk of ever reporting injection-related risk behavior by 30 months after baseline with 
95% confidence intervals (CI) at the HPTN 037 Philadelphia site, 2002-2006 (n = 651) 
 
 
 
 
 
 
 
 
 
 
 
 Index Participants Network Participants 
Network 
Randomization Total  
Person 
Shared 
“Works” 
Reported 
30-month 
Cumulative 
Incidence, 
 % 
Total 
Person 
Shared 
“Works” 
Reported 
30-month 
Cumulative 
Incidence, 
% 
Any shared works       
Treatment 112 10 9 202 28 14 
Control 120 24 20 217 42 19 
Combined Control  337 66 20    
Any risk behavior       
Treatment 112 48 43 202 75 37 
Control 120 58 48 217 97 45 
Combined Control  337 155 46    
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Table 4. Effects of the intervention on the risk of ever reporting injection-related risk behavior by 30 months after baseline with 95% 
confidence intervals (CI) at the HPTN 037 Philadelphia site, 2002-2006 (n = 651) 
 
 Stratified Models Aggregate Models 
 Unadjusted Adjusteda Unadjusted Adjusteda Unadjusted Adjusteda Unadjusted Adjusteda 
Effect RD 95% CI RD 95% CI RR 95% CI RR 95% CI RD 95% CI RD 95% CI RR 95% CI RR 95% CI 
Any shared works         
Individual −5 −16, 7 −7  −20, 5  0.65 0.28, 1.51 0.47 0.18, 1.21 −5 −16, 6 −8  −19, 3 0.65 0.28, 1.47 0.52 0.23, 1.15 
Disseminated −6  −14, 1 −5 −13, 2 0.69 0.42, 1.13 0.75 0.45, 1.25 −6 −14, 1 −5  −13, 3 0.69 0.42, 1.14 0.76 0.46, 1.25 
Composite −11  −20, −2 −13 −22, −3 0.45 0.22, 0.89 0.35 0.16, 0.78 −11 −20, −2 −13  −22, −4 0.45 0.22, 0.89 0.39 0.20, 0.78 
Overall −8  −14, −2 −8 −14, −2 0.60 0.39, 0.92 0.61 0.39, 0.94 −8 −14, −2 −8  −14, −2 0.60 0.39, 0.92 0.61 0.39, 0.94 
Any risk behaviorb               
Individual 2  −14, 18 0 −18, 17 1.07 0.73, 1.56 0.99 0.68, 1.45 2 −13, 18 0  −16, 15 1.07 0.76, 1.53 0.97 0.68, 1.39 
Disseminated −8  −18, 2 −5 −16, 5 0.83 0.64, 1.07 0.88 0.69, 1.13 −8 −18, 2 −7  −17, 4 0.83 0.64, 1.06 0.85 0.66, 1.10 
Composite −5  −18, 7 −6 −20, 8 0.89 0.67, 1.18 0.88 0.66, 1.16 −5 −18, 7 −7  −20, 6 0.89 0.67, 1.18 0.83 0.62, 1.10 
Overall −7  −15, 1 −7 −16, 2 0.85 0.69, 1.04 0.85 0.69, 1.04 −7 −15, 1 −7  −16, 2 0.85 0.69, 1.04 0.85 0.69, 1.04 
 CI = Confidence Interval; RD = Risk Difference per 100 persons; RR = Risk Ratio. 
a Adjusted for sex (male vs. female), age (years), marital status (single vs. not single), education (at least high school vs. not), and employment (unemployed vs. 
employed), and time-varying covariates set to their baseline value: crack use (yes vs. no), cocaine use (yes vs. no), benzodiazepines (yes vs. no), heroin (yes vs. 
no), drug treatment program (yes vs. no), spent the night on the street (yes vs. no), spent time in jail (yes vs. no), alcohol use (got drunk vs. not), injected heroin 
(yes vs. no), heroin and cocaine (yes vs. no), injected cocaine (yes vs. no), and number of days injected in the last month (0-5 days, 6-14 days, 15-29 days vs. 
everyday).  
b On the ratio scale, the model excluded number of days injected variable because of model convergence issues. Models for the overall effect also excluded 
injected cocaine.  Stratified model for individual, disseminated, and composite effects also excluded spent time in jail, heroin use, and injected cocaine. 
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Table 5. Six-month inter-visit incidence rate ratios and rate differences for the effect of the HPTN 037 randomized intervention on the rate of sharing 
“works” risk behavior during follow-up with 95% confidence intervals (CI) among participants with at least one follow-up visit at the Philadelphia site, 
2002-2006  
 
 Unadjusted Baseline Adjusteda,b 
RR  95% CI RD 95% CI RR 95% CI RD 95% CI 
Stratified Models 
Overallc 0.56 0.35, 0.89 -0.05 -0.10, -0.01 0.52 0.32, 0.83 -0.06 -0.11, -0.01 
Individuald 0.58 0.23, 1.48 -0.05 -0.14, 0.04 0.41 0.16, 1.06 -0.08 -0.18, 0.01 
Disseminatede 0.66 0.38, 1.12 -0.04 -0.09, 0.02 0.59 0.36, 0.97 -0.04 -0.09, 0.02 
Compositef 0.38 0.18, 0.81 -0.09 -0.16, -0.02 0.24 0.11, 0.55 -0.12 -0.19, -0.05 
Aggregate Models 
Overall 0.56 0.35, 0.89 -0.05 -0.10, -0.01 0.52 0.32, 0.83 -0.06 -0.11, -0.01 
Individual 0.56 0.25, 1.26 -0.06 -0.13, 0.02 0.55 0.25, 1.19 -0.08 -0.15, 0.00 
Disseminated 0.69 0.04, 1.17 -0.03 -0.09, 0.02 0.64 0.38, 1.08 -0.03 -0.09, 0.02 
Composite 0.39 0.18, 0.81 -0.09 -0.16, -0.02 0.35 0.17, 0.73 -0.11 -0.18, -0.04 
CI = Confidence Interval; RD = Risk Difference per 100 person-visits; RR = Risk Ratio. 
a Adjusted for sex (male vs. female), age (years), marital status (single vs. not single), education (at least high school vs. not), and 
employment (unemployed vs. employed), and time-varying covariates set to their baseline value: crack use (yes vs. no), cocaine use (yes 
vs. no), benzodiazepines (yes vs. no), smoked heroin (yes vs. no), drug treatment program (yes vs. no), spent the night on the street (yes 
vs. no), spent time in jail (yes vs. no), alcohol use (got drunk vs. not), injected heroin (yes vs. no), heroin and cocaine (yes vs. no), injected 
cocaine (yes vs. no), and number of days injected in the last month (0-5 days, 6-14 days, 15-29 days vs. everyday).  
b One participant missing information on spent the night on the street and spent time in jail at baseline.  
c There were 174 events, 1,598 person-visits and 560 people included. 
d There were 58 events, 782 person-visits and 270 people included. 
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e There were 158 events, 1,319 person-visits and 463 people included. 
f   There were 132 events, 1,095 person-visits and 387 people included. 
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Table 6.  Six-month inter-visit incidence rate ratios and rate differences for the effect of the HPTN 037 randomized intervention on the rate of any 
injection-related risk behavior during follow-up with 95% confidence intervals (CI) among participants with at least one follow-up visit at the 
Philadelphia site, 2002-2006 
 
 Unadjusted Baseline Adjusteda,b 
RR  95% CI RD 95% CI RR 95% CI RD 95% CI 
Stratified Models 
Overallc 0.72 0.57, 0.90 -0.09 -0.16, -0.02 0.69 0.56, 0.86 -0.09 -0.16, -0.03 
Individuald 0.97 0.64, 1.48 -0.02 -0.15, 0.12 0.92 0.60, 1.40 -0.06 -0.19, 0.07 
Disseminatede 0.73 0.55, 0.97 -0.09 -0.17, 0.00 0.71 0.54, 0.93 -0.08 -0.16, -0.01 
Compositef 0.71 0.52, 0.97 -0.10 -0.21, 0.00 0.65 0.47, 0.90 -0.14 -0.24, -0.03 
Aggregate Models 
Overall 0.72 0.57, 0.90 -0.09 -0.16, -0.02 0.69 0.56, 0.86 -0.09 -0.16, -0.03 
Individual 0.96 0.67, 1.39 -0.02 -0.14, 0.10 0.91 0.62, 1.33 -0.05 -0.17, 0.07 
Disseminated 0.75 0.57, 0.98 -0.08 -0.16, 0.00 0.72 0.55, 0.94 -0.08 -0.16, 0.01 
Composite 0.72 0.53, 0.98 -0.10 -0.21, 0.01 0.65 0.47, 0.90 -0.13 -0.23, -0.02 
CI = Confidence Interval; RD = Risk Difference per 100 person-visits; RR = Risk Ratio. 
a Adjusted for sex (male vs. female), age (years), marital status (single vs. not single), education (at least high school vs. not), and employment 
(unemployed vs. employed), and time-varying covariates set to their baseline value: crack use (yes vs. no), cocaine use (yes vs. no), benzodiazepines 
(yes vs. no), smoked heroin (yes vs. no), drug treatment program (yes vs. no), spent the night on the street (yes vs. no), spent time in jail (yes vs. no), 
alcohol use (got drunk vs. not), injected heroin (yes vs. no), heroin and cocaine (yes vs. no), injected cocaine (yes vs. no), and number of days injected in 
the last month (0-5 days, 6-14 days, 15-29 days vs. everyday).  
b One participant missing information on spent the night on the street and spent time in jail at baseline.   
c There were 509 events, 1,598 person-visits and 560 people included. 
d There were 204 events, 782 person-visits and 270 people included. 
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e There were 433 events, 1,319 person-visits and 463 people included. 
f There were 381 events, 1,095 person-visits and 387 people included.  
